“Increased Screening in Low-Prevalence Countries”
- The latent TB testing market is projected to grow steadily, driven by the increasing prevalence of latent TB infections and advancements in diagnostic technologies such as IGRA tests and TSTs
- Immunocompromised individuals, such as those with HIV/AIDS or undergoing organ transplants, are contributing to the rising demand for latent TB testing
- For instance, in April 2024, Revvity launched the Auto-Pure 2400 system to enhance the efficiency of latent TB testing, combining accuracy with streamlined workflows
- International organizations and governments are investing in TB control programs, promoting early detection and preventive measures for latent TB
- The latent TB testing market is poised for growth, driven by increasing awareness, technological advancements, and global efforts to combat tuberculosis effectively
